A recent safety and systematic review on the use of sclerostin for the management of osteoporosis reveals increases in bone mineral density between 13.1 and 13.3 % at lumbar level, 2.2–5.9 % and 2.5–6.9 % at femoral neck and total hip, respectively, along a reduction of vertebral, main and hip fractures [63]. This evidence concerns the gene SOST and osteoporosis.